Bullish & Foolish
Full SNOA fundamentals All 466 on the Survival Watch

SNOASONOMA PHARMACEUTICALS, INC.

Is Sonoma Pharmaceuticals struggling financially?

Yes, by its own account. Sonoma Pharmaceuticals told the SEC on 10 Feb 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Feb 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$6.4M
Source filing
10-Q 10 Feb 2026
Balance sheet
30 Jun 2026

Cash runway

  • 13months

    If the burn speeds up

    Empty by Jul 2027

  • 18months

    If it eases off

    Empty by Dec 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$5.3M

÷

Cash burned over the last 12 months

$4.1M

What Sonoma Pharmaceuticals told the SEC

…of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be…

SONOMA PHARMACEUTICALS, INC., Form 10-Q, filed 10 Feb 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 134.4% share-count increase The company issued stock. Each share now owns 57.3% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 43% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt